Citadel Advisors
HRTX icon

Citadel Advisors’s Heron Therapeutics HRTX Stock Holding History

Citadel Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.7K Buy
34,600
+17,200
+99% +$19.9K ﹤0.01% 12595
2025
Q4 		$22.6K Buy
+17,400
New +$21.5K ﹤0.01% 12311
2025
Q3 		– Sell
-41,000
Closed -$84.9K – 13346
2025
Q2 		$84.9K Buy
41,000
+38,900
+1,852% +$79.4K ﹤0.01% 11447
2025
Q1 		$4.62K Sell
2,100
-49,400
-96% -$95.9K ﹤0.01% 13877
2024
Q4 		$78.8K Buy
51,500
+11,300
+28% +$18.3K ﹤0.01% 11808
2024
Q3 		$80K Buy
40,200
+1,700
+4% +$4.06K ﹤0.01% 11412
2024
Q2 		$135K Buy
38,500
+17,900
+87% +$55K ﹤0.01% 10498
2024
Q1 		$57.1K Sell
20,600
-61,300
-75% -$154K ﹤0.01% 12048
2023
Q4 		$139K Buy
81,900
+70,600
+625% +$77.7K ﹤0.01% 10501
2023
Q3 		$11.6K Sell
11,300
-5,100
-31% -$7.26K ﹤0.01% 12999
2023
Q2 		$19K Buy
16,400
+8,200
+100% +$14.6K ﹤0.01% 12769
2023
Q1 		$12.4K Sell
8,200
-11,000
-57% -$27.5K ﹤0.01% 13417
2022
Q4 		$48K Sell
19,200
-22,300
-54% -$71.8K ﹤0.01% 12194
2022
Q3 		$175K Buy
41,500
+30,300
+271% +$119K ﹤0.01% 10542
2022
Q2 		$31K Sell
11,200
-16,600
-60% -$66.7K ﹤0.01% 12197
2022
Q1 		$159K Sell
27,800
-6,200
-18% -$45.4K ﹤0.01% 11788
2021
Q4 		$310K Sell
34,000
-29,800
-47% -$304K ﹤0.01% 10853
2021
Q3 		$682K Sell
63,800
-8,600
-12% -$105K ﹤0.01% 9132
2021
Q2 		$1.12M Sell
72,400
-105,400
-59% -$1.68M ﹤0.01% 8060
2021
Q1 		$2.88M Buy
177,800
+96,200
+118% +$1.71M ﹤0.01% 5540
2020
Q4 		$1.73M Buy
81,600
+59,100
+263% +$1.03M ﹤0.01% 5659
2020
Q3 		$333K Sell
22,500
-75,000
-77% -$1.17M ﹤0.01% 7955
2020
Q2 		$1.43M Buy
97,500
+13,200
+16% +$217K ﹤0.01% 5159
2020
Q1 		$990K Buy
84,300
+54,500
+183% +$1.02M ﹤0.01% 5351
2019
Q4 		$700K Sell
29,800
-3,800
-11% -$84.1K ﹤0.01% 6240
2019
Q3 		$622K Sell
33,600
-700
-2% -$12.9K ﹤0.01% 6387
2019
Q2 		$638K Sell
34,300
-320,200
-90% -$6.4M ﹤0.01% 6434
2019
Q1 		$8.66M Buy
354,500
+324,200
+1,070% +$8.49M ﹤0.01% 2250
2018
Q4 		$786K Sell
30,300
-25,700
-46% -$707K ﹤0.01% 5682
2018
Q3 		$1.77M Sell
56,000
-10,100
-15% -$376K ﹤0.01% 4605
2018
Q2 		$2.57M Buy
66,100
+9,300
+16% +$296K ﹤0.01% 3715
2018
Q1 		$1.57M Buy
56,800
+25,900
+84% +$588K ﹤0.01% 4099
2017
Q4 		$559K Buy
30,900
+8,000
+35% +$130K ﹤0.01% 5488
2017
Q3 		$370K Buy
22,900
+8,700
+61% +$136K ﹤0.01% 5744
2017
Q2 		$197K Buy
+14,200
New +$206K ﹤0.01% 6580
2017
Q1 		– Sell
-27,200
Closed -$356K – 7696
2016
Q4 		$356K Sell
27,200
-800
-3% -$12.6K ﹤0.01% 5428
2016
Q3 		$482K Buy
28,000
+2,800
+11% +$52K ﹤0.01% 4918
2016
Q2 		$455K Sell
25,200
-13,000
-34% -$254K ﹤0.01% 4620
2016
Q1 		$725K Buy
38,200
+29,600
+344% +$584K ﹤0.01% 3882
2015
Q4 		$230K Sell
8,600
-43,000
-83% -$1.15M ﹤0.01% 5616
2015
Q3 		$1.26M Buy
51,600
+19,000
+58% +$633K ﹤0.01% 3515
2015
Q2 		$1.02M Buy
32,600
+11,400
+54% +$214K ﹤0.01% 3944
2015
Q1 		$308K Buy
21,200
+10,700
+102% +$121K ﹤0.01% 5607
2014
Q4 		$106K Buy
+10,500
New +$85.7K ﹤0.01% 6589

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Citadel Advisors's HRTX Position: Q1 2026 in Review

Citadel Advisors reduced its Heron Therapeutics (HRTX) stake by 64% in Q1 2026, selling an estimated $1.55M and leaving 759,269 shares worth $607K. The position accounts for ﹤0.01% of the portfolio, ranked #8817.

Citadel Advisors first reported a position in HRTX in Q4 2014 and has held it in 43 quarters since. The position peaked at $68.5M in Q4 2018. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Citadel Advisors held 759,269 shares of Heron Therapeutics worth $607K as of Q1 2026.
  • Citadel Advisors sold 1,335,776 Heron Therapeutics shares in Q1 2026, an estimated $1.55M.
  • Heron Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8817 holding.
  • Citadel Advisors first reported a position in Heron Therapeutics in Q4 2014 and has held it in 43 quarters since.
  • Citadel Advisors's Heron Therapeutics position peaked at $68.5M in Q4 2018.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.